1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Market Access for Orphan Drugs: assessing the global landscape

  • December 2013
  • 100 pages
  • Firstword Pharma
Report ID: 3509418

Summary

Table of Contents




Their development costs can be high and the market is relative small, yet orphan drugs represent a significant contribution to public health—and the pharmaceutical market.

In fact, analysts predict that orphan drugs will account for 15 percent of the global pharmaceutical market by 2018. Yet getting there will not be easy. While governments offer incentives for development, payers must also balance the needs of the majority with the high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies.

In Market Access for Orphan Drugs: assessing the global landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the US, Asia and Europe. Based on thorough research and European national drug policies translated specifically for FirstWord, the report reviews the challenges, offers insight into strategies being used and includes invaluable comparative tables. Filled with information on trends, patient access schemes and the role of patient organisations, the report is a must-read for orphan drug developers and manufacturers.








Key Report Features of Market Access for Orphan Drugs: assessing the global landscape include:


Comparative tables for orphan drug polices and incentives in the major markets
A look at the role of patient organisations and registries in orphan drug development
Pricing and reimbursement information for key markets
Overview of orphan drug trends by year, company and therapeutic focus





Key Benefits


Developing and marketing orphan drugs poses several challenges. Through Market Access for Orphan Drugs: assessing the global landscape, you will:


Understand the regulatory and policy frameworks that exist in key markets
Gain insight into the incentives available to orphan drug developers
Appreciate the role of patient groups as potential collaborators in new therapy development
Access information relating to which companies are successfully operating in the orphan drug arena



Getting Your Orphan Drug to Market answers key questions:


Which countries have orphan drug-specific regulations and how are they harmonised?
What incentives are offered to European and American orphan drug developers?
How does orphan drug designationvary from market to market?
How does pricing and reimbursement differ between the general drug market and orphan drugs?








Key facts

By 2020, the recently-formed International Rare Disease Research Consortium aims to be able to diagnose most rare diseases and to have developed 200 new therapies
Biomarkers and improved clinical diagnostics are increasing the possibility of developing targeted rare disease therapies
Currently, there are 6,000 to 8,000 rare diseases, with genetic research identifying more
Although the prevalence of rare disease is extremely low, they affect 30 million people in the EU


Content Highlights


As the orphan drug industry faces new opportunities and challenges, you will discover:

The importance of patient groups in both advocacy and collaborations
How regulations and incentives vary from country to country
The concerted efforts by regulatory agencies to harmonize certain aspects of orphan drug regulations in order to ease sponsors’ journey through requirements








Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Clinical Chemistry Reagents and Analyzers Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 75000
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 74-country report from VPGMarketResearch.com is available by region, country, market segment, section, or individual test. Please contact Client Services at reports@vpgcorp.com or +1 212 564 ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.